Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies
- 14 November 2003
- journal article
- review article
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 217 (1-2) , 53-58
- https://doi.org/10.1016/j.mce.2003.10.009
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: Role of vascular superoxide anion formation and endothelial nitric oxide synthase expressionJournal of the American College of Cardiology, 2002
- Endothelial Cell Dysfunction in Mice After Transgenic Knockout of Type 2, but Not Type 1, 11β-Hydroxysteroid DehydrogenaseCirculation, 2001
- Mineralocorticoid Receptor Affects AP-1 and Nuclear Factor-κB Activation in Angiotensin II–Induced Cardiac InjuryHypertension, 2001
- Mineralocorticoid receptor antagonists: The evolution of utility and pharmacologyKidney International, 2000
- Spironolactone Increases Nitric Oxide Bioactivity, Improves Endothelial Vasodilator Dysfunction, and Suppresses Vascular Angiotensin I/Angiotensin II Conversion in Patients With Chronic Heart FailureCirculation, 2000
- Synergistic Effect of Adrenal Steroids and Angiotensin II on Plasminogen Activator Inhibitor-1 ProductionJournal of Clinical Endocrinology & Metabolism, 2000
- 11β-Hydroxysteroid Dehydrogenase in Cultured Human Vascular CellsHypertension, 1999
- Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patientsCardiovascular Research, 1997
- VASCULAR TYPE I ALDOSTERONE BINDING SITES ARE PHYSIOLOGICAL MINERALOCORTICOID RECEPTORSEndocrinology, 1989
- Mineralocorticoid Action: Target Tissue Specificity Is Enzyme, Not Receptor, MediatedScience, 1988